BSR_12_0194_A1_S68
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- INTERFERON_ALPHA_RESPONSE+0.350
- MYOGENESIS+0.270
- COAGULATION+0.260
- APOPTOSIS+0.240
- INTERFERON_GAMMA_RESPONSE+0.230
- ANGIOGENESIS+0.210
- PROTEIN_SECRETION+0.160
- HEDGEHOG_SIGNALING+0.150
- TNFA_SIGNALING_VIA_NFKB+0.130
Top 10 suppressed
- E2F_TARGETS-0.330
- G2M_CHECKPOINT-0.320
- MTORC1_SIGNALING-0.250
- PI3K_AKT_MTOR_SIGNALING-0.190
- ADIPOGENESIS-0.170
- ANDROGEN_RESPONSE-0.160
- CHOLESTEROL_HOMEOSTASIS-0.120
- FATTY_ACID_METABOLISM-0.120
- MYC_TARGETS_V1-0.110
- MYC_TARGETS_V2-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A10F-01A-11R-A10J-07 | — | A | 0.766 |
| 2 | TCGA-44-2665-01A-01R-0946-07 | — | cohortA1 | 0.765 |
| 3 | TCGA-XF-AAN4-01A-11R-A42T-07 | — | — | 0.748 |
| 4 | c6396737-3587-46a7-808d-963eebe41224 | — | — | 0.743 |
| 5 | 4925248f-21e2-476e-937c-02e0a748c77b | — | — | 0.736 |
| 6 | TCGA-XF-A9SW-01A-11R-A42T-07 | — | — | 0.735 |
| 7 | 52a10f37-ee39-4805-908e-b9e35fa983e9 | — | — | 0.734 |
| 8 | 802f1041-19bc-4bec-8452-5e4b19a8100e | — | — | 0.731 |
| 9 | TCGA-D8-A73W-01A-22R-A352-07 | — | B | 0.729 |
| 10 | SRR17866819 | — | — | 0.729 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.230 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.160 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.120 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.120 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.110 | Idelalisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |